Skip to content
Start your journey

After ovarian cancer treatment

Why CA-125 monitoring is more controversial than people expect, what symptoms actually matter, surgical menopause, genetic testing and maintenance treatment.

4 min read · Part of Cancer Types

Written by The LifeAfterward editorial team from the sources listed at the end of this page.

Not individually reviewed by a clinician. This page is written from published clinical guidance, listed in full at the end, and is general information rather than medical advice — your own team knows your case. See our editorial standards.

Last checked against its sources · Last updated · Next check due

In short

  • Follow-up is examination and symptom led. Routine CA-125 monitoring is offered in some services and deliberately not in others, for reasons based on trial evidence.
  • Genetic testing is recommended for most people with ovarian cancer, and the result can change both your treatment and your family’s screening.
  • Maintenance treatment after chemotherapy — including PARP inhibitors for some — is now common and has its own monitoring.
  • Surgery often causes immediate menopause, which is more abrupt than the natural version and deserves proper management.

What this means

Ovarian cancer follow-up asks people to live with more uncertainty than most: recurrence is common, the main blood test is of debated value, and the symptoms to watch for are vague ones everybody occasionally has. Knowing why the plan is what it is makes it considerably easier to live with.

The CA-125 question

CA-125 is a blood marker that often rises before symptoms of recurrence appear. It sounds like an unambiguous good thing, and a large randomised trial complicated it: treating recurrence early on the basis of a rising CA-125, before symptoms, did not improve survival compared with waiting for symptoms, and meant more months of chemotherapy and worse quality of life.

  • That is why some services monitor CA-125 routinely and others offer it only if you want it, or not at all. Both positions are evidence-based.
  • It is a reasonable thing to have a considered conversation about: some people want to know as early as possible, others would rather have symptom-free months.
  • CA-125 can rise for benign reasons, and it is not raised at all in some ovarian cancers.
  • Whatever is decided, symptoms remain the thing that matters most between appointments.

The symptoms that matter

  • Persistent bloating, or clothes becoming tight around the abdomen.
  • Abdominal or pelvic pain that persists.
  • Feeling full quickly, loss of appetite, or unexplained weight change.
  • Needing to pass urine more often or more urgently.
  • A change in bowel habit, or new constipation with pain and vomiting.
  • Persistent fatigue or breathlessness.

Genetics and maintenance treatment

  • Genetic testing — including BRCA1 and BRCA2, and sometimes tumour testing — is recommended for most people with ovarian cancer. If it was not discussed, ask.
  • A result can affect which maintenance treatments are options for you, and gives relatives the chance to be tested and screened.
  • PARP inhibitor maintenance is used after chemotherapy in some situations; it involves regular blood tests and its own side effects, which are manageable but worth reporting early.
  • Ask what happens at the end of maintenance, which many people find as unsettling as the end of chemotherapy.

Menopause, bowels and body

  • Removal of the ovaries causes immediate menopause. It is abrupt and often more intense than natural menopause — see menopause caused by treatment, and ask whether HRT is appropriate for your cancer type, because for some it is.
  • Bone and heart health matter more after early menopause; ask about a DXA scan and cardiovascular checks.
  • Vaginal dryness and painful sex are common and very treatable — see sex and intimacy.
  • Abdominal surgery can leave adhesions; new colicky pain with vomiting and no bowel movement needs urgent assessment.
  • Lymphoedema can follow pelvic node surgery — see lymphoedema.
  • Fertility loss is a real bereavement, whatever the circumstances. See fertility after treatment.

What to ask your healthcare team

  • Is CA-125 part of my follow-up, and what is the reasoning either way?
  • Which symptoms should I report, and after how long?
  • Have I had genetic testing, and should my family be offered it?
  • Am I eligible for maintenance treatment, and what does it involve?
  • Can I take HRT, given my cancer type?
  • Do I need bone density or cardiovascular monitoring after surgical menopause?

Save questions to My Journey so you have them in the room, or use a ready-made list.

When to seek medical advice

Contact your healthcare team if you have:

  • Persistent bloating, abdominal pain or feeling full quickly, lasting more than two or three weeks.
  • Change in bowel or bladder habit that persists.
  • Unexplained weight loss or increasing fatigue.
  • New leg swelling.
  • Menopausal symptoms severe enough to affect sleep, work or relationships.

Get emergency help the same day if you have:

  • Severe abdominal pain with vomiting and no bowel movement or wind — possible obstruction, needs emergency assessment.
  • A hot, swollen, painful calf, or sudden breathlessness or chest pain — possible clot.

If you are worried and unsure, contact your team anyway — they would far rather hear from you unnecessarily than late. What to do in an emergency.

Common questions

Should I have CA-125 monitoring after ovarian cancer?

It depends on your service and on you. A large randomised trial found that treating recurrence early on the basis of a rising CA-125, before symptoms appeared, did not improve survival and meant more chemotherapy and worse quality of life — which is why some teams monitor routinely and others do not. It is worth a considered conversation rather than an assumption either way.

Can I take HRT after ovarian cancer?

For some types, yes — and surgical menopause at a young age carries its own long-term bone and heart risks, which is part of the calculation. It depends on the specific cancer, so ask your oncology team, ideally alongside a menopause specialist.

Sources

This page was written from the guidance below and checked against it on . Links are re-checked at each review — see our editorial standards.

  1. ASCO (Cancer.Net). Survivorship
  2. National Comprehensive Cancer Network. NCCN Guidelines for Patients
  3. National Cancer Institute (US). Follow-up medical care after cancer treatment
  4. European Society for Medical Oncology. ESMO patient guides
  5. National Cancer Institute (US). Late effects of cancer treatment
fertility & sexual healthMenopause caused by cancer treatmentMenopause that arrives suddenly because of chemotherapy, surgery or hormone therapy is more intense than natural menopause. What helps, and what to do when HRT is not an option.4 min readlong term effectsLymphoedema after cancer treatmentSwelling after lymph node surgery or radiotherapy is manageable, and far more so when caught early. What to watch for, what treatment involves, and where the old advice has changed.5 min readfollow upWhat follow-up care actually involvesWho you see, how often, what they are checking for, and why fewer scans is usually a sign of good care rather than neglect.6 min readliving with cancerSecondary cancer: what the words actually meanSecondary, metastatic, advanced, stage 4, treatable but not curable — what each phrase means, what scan reports are saying, and what "lines of treatment" is describing.6 min read